Cargando…

Modeling Early Heterogeneous Rates of Progression in Boys with Duchenne Muscular Dystrophy

BACKGROUND: Duchenne muscular dystrophy (DMD) exhibits substantial variability in rates of disease progression and response to treatment. This has hindered treatment development and complicated interpretation of drug effects in clinical trials. OBJECTIVE: We hypothesized that a multivariate combinat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Yuan, McDonald, Craig M., Clemens, Paula R., Gordish, Heather-Dressman, Illei, Kate, Hoffman, Eric P., Dang, Utkarsh J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2023
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200136/ https://www.ncbi.nlm.nih.gov/pubmed/36806514 http://dx.doi.org/10.3233/JND-221527

Ejemplares similares

Comparison of Serum Pharmacodynamic Biomarkers in Prednisone-Versus Deflazacort-Treated Duchenne Muscular Dystrophy Boys
por: Tawalbeh, Shefa, et al.
Publicado: (2020)

Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy
por: Hathout, Yetrib, et al.
Publicado: (2019)

Neurodevelopmental Needs in Young Boys with Duchenne Muscular Dystrophy (DMD): Observations from the Cooperative International Neuromuscular Research Group (CINRG) DMD Natural History Study (DNHS).
por: Thangarajh, Mathula, et al.
Publicado: (2018)

Suitability of external controls for drug evaluation in Duchenne muscular dystrophy
por: Goemans, Nathalie, et al.
Publicado: (2020)

Serum biomarkers associated with baseline clinical severity in young steroid-naïve Duchenne muscular dystrophy boys
por: Dang, Utkarsh J, et al.
Publicado: (2020)

Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy
por: Khan, Navid, et al.
Publicado: (2019)

Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy
por: Hathout, Yetrib, et al.
Publicado: (2015)

Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy
por: Hogarth, Marshall W., et al.
Publicado: (2017)

Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients
por: McDonald, Craig M, et al.
Publicado: (2021)

Exon-Skipping in Duchenne Muscular Dystrophy
por: Takeda, Shin’ichi, et al.
Publicado: (2021)

Duchenne Regulatory Science Consortium Meeting on Disease Progression Modeling for Duchenne Muscular Dystrophy
por: Larkindale, Jane, et al.
Publicado: (2017)

Validation of Chemokine Biomarkers in Duchenne Muscular Dystrophy
por: Ogundele, Michael, et al.
Publicado: (2021)

Genetic modifiers of upper limb function in Duchenne muscular dystrophy
por: Sabbatini, Daniele, et al.
Publicado: (2022)

Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study
por: Clemens, Paula R., et al.
Publicado: (2023)

Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study
por: Smith, Edward C., et al.
Publicado: (2020)

Genetic modifiers of respiratory function in Duchenne muscular dystrophy
por: Bello, Luca, et al.
Publicado: (2020)

Growth pattern trajectories in boys with Duchenne muscular dystrophy
por: Stimpson, Georgia, et al.
Publicado: (2022)

Language Development in Preschool Duchenne Muscular Dystrophy Boys
por: Chieffo, Daniela Pia Rosaria, et al.
Publicado: (2022)

Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy
por: Biggar, W. Douglas, et al.
Publicado: (2022)

Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial
por: Mah, Jean K., et al.
Publicado: (2022)

Hypokalemia complicating Duchenne muscular dystrophy.
por: McDonald, B., et al.
Publicado: (1987)

Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function
por: Hoffman, Eric P., et al.
Publicado: (2019)

Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy
por: Clemens, Paula R., et al.
Publicado: (2022)

Skeletal disproportion in glucocorticoid-treated boys with Duchenne muscular dystrophy
por: Kao, Kung-Ting, et al.
Publicado: (2019)

Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial
por: Clemens, Paula R., et al.
Publicado: (2020)

Muscular response to the first three months of deflazacort treatment in boys with Duchenne muscular dystrophy
por: Jensen, L., et al.
Publicado: (2017)

24 Month Longitudinal Data in Ambulant Boys with Duchenne Muscular Dystrophy
por: Mazzone, Elena Stacy, et al.
Publicado: (2013)

Therapeutic effects of aquatic exercises on a boy with Duchenne muscular dystrophy
por: Atamturk, Hakan, et al.
Publicado: (2018)

Transaminitis in a Three-year-old Boy with Duchenne Muscular Dystrophy
por: Xie, Qiuli, et al.
Publicado: (2020)

Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial
por: Guglieri, Michela, et al.
Publicado: (2022)

Theragnosis for Duchenne Muscular Dystrophy
por: Luce, Leonela, et al.
Publicado: (2021)

Reply to F. Muntoni et al.: “In response to P.R. Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy
por: Clemens, Paula R., et al.
Publicado: (2023)

Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study
por: Boca, Simina M., et al.
Publicado: (2016)

Physical training in boys with Duchenne Muscular Dystrophy: the protocol of the No Use is Disuse study
por: Jansen, Merel, et al.
Publicado: (2010)

Correction: 24 Month Longitudinal Data in Ambulant Boys with Duchenne Muscular Dystrophy
por: Mazzone, Elena Stacy, et al.
Publicado: (2013)

Revised North Star Ambulatory Assessment for Young Boys with Duchenne Muscular Dystrophy
por: Mercuri, Eugenio, et al.
Publicado: (2016)

Bioelectrical impedance vector analysis and phase angle in boys with Duchenne muscular dystrophy
por: Vermeulen, Karina M., et al.
Publicado: (2019)

Celiac Disease in a Boy with Duchenne Muscular Dystrophy: A Double Jeopardy!
por: Sharawat, Indar K., et al.
Publicado: (2020)

Effects of Bisphosphonate Therapy on Bone Mineral Density in Boys with Duchenne Muscular Dystrophy
por: Ronsley, Rebecca, et al.
Publicado: (2020)

Eteplirsen Use in a Boy with Duchenne Muscular Dystrophy and Sickle Cell Anemia
por: Aiello, Gregory M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q8not9dj5q72atjkoo705396ub